Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.
Cancer Lett. 2014 Oct 28;353(2):248-57 Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol. Georgakilas AG1, Redon CE2, Ferguson NF3, Kryston TB3, Parekh P2, Dickey JS4, Nakamura AJ5, Mitchell JB6, Bonner WM2, Martin OA7. 1Department of Biology, Thomas Harriot College of Arts and Sciences, East Carolina University, Greenville, […]Take a Tour
Int J Clin Exp Med. 2014 Apr 15;7(4):982-8 Tempol protects human lymphocytes from genotoxicity induced by cisplatin. Khabour OF1, Alzoubi KH2, Mfady DS1, Alasseiri M1, Hasheesh TF1. 1Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology Irbid, Jordan. 2Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of […]Take a Tour
Clin Chem Lab Med. 2008;46(6):836-41. Antioxidant defense capacity in scleroderma patients. Sfrent-Cornateanu R1, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E. 1Department of Physiopathology and Immunology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania. Abstract BACKGROUND: Oxidative stress is associated with scleroderma (systemic sclerosis) and is supposed to favor disease progression by […]Take a Tour
Int J Clin Pharmacol Res. 1985;5(1):59-62. Intrathecal orgotein. Lund-Olesen K. Abstract During the period 1971-78, 133 intrathecal injections of orgotein or superoxide dismutase have been given, mostly to patients with multiple sclerosis. Evaluation of the effect was deficient but the impression was that of improvement and 45% of the 58 patients with multiple sclerosis requested […]Take a Tour
J Invest Dermatol. 2004 Mar;122(3):594-601. Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma. Nagai M1, Hasegawa M, Takehara K, Sato S. 1Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. Abstract Abnormal production of reactive oxygen species (ROS) induces tissue damage and superoxide dismutase (SOD) that converts superoxide radicals […]Take a Tour
Drugs Exp Clin Res. 1991;17(2):127-31. Topical application of superoxide dismutase cream. Mizushima Y1, Hoshi K, Yanagawa A, Takano K. 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan. Abstract A superoxide dismutase (SOD) cream containing 0.6 mg/ml of bovine SOD was prepared. It was applied locally onto the skin and mucosal lesions […]Take a Tour
A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy.
Clin Cancer Res. 2004 Oct 1;10(19):6411-7. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Metz JM¹, Smith D, Mick R, Lustig R, Mitchell J, Cherakuri M, Glatstein E, Hahn SM. ¹Department of Radiation Oncology, University of Pennsylvania, Philadelphia Abstract PURPOSE: Complete alopecia is a universal complication […]Take a Tour
Antioxid Redox Signal. 2007 Oct;9(10):1731-43. Forum Review: Therapeutic and clinical applications of nitroxide compounds. Soule BP¹, Hyodo F, Matsumoto K, Simone NL, Cook JA, Krishna MC, Mitchell JB. ¹ Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland Abstract Nitroxide compounds have been used for many years as biophysical tools, but only […]Take a Tour
J Invest Dermatol. 1989 Oct;93(4):506-10. Reduced superoxide dismutase activity in xeroderma pigmentosum fibroblasts. Nishigori C¹, Miyachi Y, Imamura S, Takebe H. ¹Department of Dermatology, Faculty of Medicine, Kyoto University, Japan. Abstract This study was performed in order to assess the possible protective effect of superoxide dismutase (SOD) on ultraviolet (UV) damage in xeroderma pigmentosum […]Take a Tour
FOR IMMEDIATE RELEASE August 19, 2014 Fibrocystic disease may affect up to 50 percent of all women (INDIANAPOLIS, Ind.) –A new patent has been issued for a method that uses the SOD-mimetic agent TEMPOL to treat fibrocystic disease of the breast (FD). Approximately 20 percent of women suffering from FD, which is more commonly known […]Take a Tour